Bevacizumab intravítreo en el tratamiento de la neovascularización subretiniana secundaria a rotura coroidea

Translated title of the contribution: Use of intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to choroidal rupture

X. Valldeperas, R. Bonilla, M. R. Romano, J. De La Cámara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Case report: A 28 year-old male attended our Emergency Department with a traumatic choroidal rupture and macular haemorrhage. After pneumatic displacement of the haemorrhage with C 3F 8 and tissue plasminogen activator, the haemorrhage was reabsorbed and visual acuity (VA) improved. Three months later the patient presented with decreased VA and a juxtafoveal choroidal neovascularisation (CNV) that was treated with intravitreal bevacizumab. One year after a single bevacizumab injection the CNV remained inactive, with a final VA of 0.5. Discussion: Intravitreal bevacizumab injection is a new and effective treatment for traumatic CNV. In our patient, in contrast to other aetiologies, the CNV needed no more than one Avastin ® injection to be inactivated, after one year of follow-up.

Original languageSpanish
Pages (from-to)380-383
Number of pages4
JournalArchivos de la Sociedad Espanola de Oftalmologia
Volume86
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Choroidal Neovascularization
Rupture
Visual Acuity
Hemorrhage
Intravitreal Injections
Injections
Tissue Plasminogen Activator
Therapeutics
Hospital Emergency Service
Bevacizumab

Keywords

  • Bevacizumab
  • Choroidal neovascularisation
  • Choroidal rupture
  • Ocular traumatism
  • Pneumatic displacement
  • Recombinant tissue plasminogen activator (rTPA)
  • Submacular haemorrhage

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Bevacizumab intravítreo en el tratamiento de la neovascularización subretiniana secundaria a rotura coroidea. / Valldeperas, X.; Bonilla, R.; Romano, M. R.; De La Cámara, J.

In: Archivos de la Sociedad Espanola de Oftalmologia, Vol. 86, No. 11, 11.2011, p. 380-383.

Research output: Contribution to journalArticle

Valldeperas, X. ; Bonilla, R. ; Romano, M. R. ; De La Cámara, J. / Bevacizumab intravítreo en el tratamiento de la neovascularización subretiniana secundaria a rotura coroidea. In: Archivos de la Sociedad Espanola de Oftalmologia. 2011 ; Vol. 86, No. 11. pp. 380-383.
@article{827e7b9b59c8430f8e1e2a14e647bba2,
title = "Bevacizumab intrav{\'i}treo en el tratamiento de la neovascularizaci{\'o}n subretiniana secundaria a rotura coroidea",
abstract = "Case report: A 28 year-old male attended our Emergency Department with a traumatic choroidal rupture and macular haemorrhage. After pneumatic displacement of the haemorrhage with C 3F 8 and tissue plasminogen activator, the haemorrhage was reabsorbed and visual acuity (VA) improved. Three months later the patient presented with decreased VA and a juxtafoveal choroidal neovascularisation (CNV) that was treated with intravitreal bevacizumab. One year after a single bevacizumab injection the CNV remained inactive, with a final VA of 0.5. Discussion: Intravitreal bevacizumab injection is a new and effective treatment for traumatic CNV. In our patient, in contrast to other aetiologies, the CNV needed no more than one Avastin {\circledR} injection to be inactivated, after one year of follow-up.",
keywords = "Bevacizumab, Choroidal neovascularisation, Choroidal rupture, Ocular traumatism, Pneumatic displacement, Recombinant tissue plasminogen activator (rTPA), Submacular haemorrhage",
author = "X. Valldeperas and R. Bonilla and Romano, {M. R.} and {De La C{\'a}mara}, J.",
year = "2011",
month = "11",
doi = "10.1016/j.oftal.2011.05.019",
language = "Spagnolo",
volume = "86",
pages = "380--383",
journal = "Archivos de la Sociedad Espanola de Oftalmologia",
issn = "0365-6691",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Bevacizumab intravítreo en el tratamiento de la neovascularización subretiniana secundaria a rotura coroidea

AU - Valldeperas, X.

AU - Bonilla, R.

AU - Romano, M. R.

AU - De La Cámara, J.

PY - 2011/11

Y1 - 2011/11

N2 - Case report: A 28 year-old male attended our Emergency Department with a traumatic choroidal rupture and macular haemorrhage. After pneumatic displacement of the haemorrhage with C 3F 8 and tissue plasminogen activator, the haemorrhage was reabsorbed and visual acuity (VA) improved. Three months later the patient presented with decreased VA and a juxtafoveal choroidal neovascularisation (CNV) that was treated with intravitreal bevacizumab. One year after a single bevacizumab injection the CNV remained inactive, with a final VA of 0.5. Discussion: Intravitreal bevacizumab injection is a new and effective treatment for traumatic CNV. In our patient, in contrast to other aetiologies, the CNV needed no more than one Avastin ® injection to be inactivated, after one year of follow-up.

AB - Case report: A 28 year-old male attended our Emergency Department with a traumatic choroidal rupture and macular haemorrhage. After pneumatic displacement of the haemorrhage with C 3F 8 and tissue plasminogen activator, the haemorrhage was reabsorbed and visual acuity (VA) improved. Three months later the patient presented with decreased VA and a juxtafoveal choroidal neovascularisation (CNV) that was treated with intravitreal bevacizumab. One year after a single bevacizumab injection the CNV remained inactive, with a final VA of 0.5. Discussion: Intravitreal bevacizumab injection is a new and effective treatment for traumatic CNV. In our patient, in contrast to other aetiologies, the CNV needed no more than one Avastin ® injection to be inactivated, after one year of follow-up.

KW - Bevacizumab

KW - Choroidal neovascularisation

KW - Choroidal rupture

KW - Ocular traumatism

KW - Pneumatic displacement

KW - Recombinant tissue plasminogen activator (rTPA)

KW - Submacular haemorrhage

UR - http://www.scopus.com/inward/record.url?scp=80255136150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80255136150&partnerID=8YFLogxK

U2 - 10.1016/j.oftal.2011.05.019

DO - 10.1016/j.oftal.2011.05.019

M3 - Articolo

VL - 86

SP - 380

EP - 383

JO - Archivos de la Sociedad Espanola de Oftalmologia

JF - Archivos de la Sociedad Espanola de Oftalmologia

SN - 0365-6691

IS - 11

ER -